

### **HCV** Action e-update

Bringing you the latest hepatitis C news and events


### December 2016

HCV Action brings together hepatitis C health professionals from across the patient pathway with the pharmaceutical industry and patient representatives to share expertise and good practice.

#### News & reports...

- \* Public Health England, in joint partnership with professional organisations, has published a consultation asking for feedback in relation to the Standards for Microbiology Investigations V 5: Screening for hepatitis C infection. The consultation closes on 15<sup>th</sup> December at 5pm and can be accessed here.
- \* The <u>University of Birmingham</u> has announced a two-day course, <u>Liver Disease in Primary Care</u>, which aims to provide theoretical and practical knowledge of liver diseases and how to manage them in primary care. The course will be led by Professor Phil Newsome, Professor of Hepatology at the University of Birmingham and will be held on Tuesday 21<sup>st</sup> and Wednesday 22<sup>nd</sup> March 2017. Full details and booking information available here.
- \* New to the <u>HCV Action</u> Resource Library this month is '<u>Drug-related infectious diseases in Europe</u>', the latest update on infectious diseases related to drug use in Europe for the period up to June 2016. Produced by the <u>European Monitoring Centre for Drugs and Drug Addiction</u>, the report can be accessed <u>here</u>.
- \* Also added to the <u>HCV Action</u> Resource Library this month was 'The lived experience of interferonfree treatments for hepatitis C: A <u>thematic analysis</u>', a new research paper published in the

## New Hepatitis C Commissioning Toolkit launched



HCV Action has this week launched a Hepatitis C Commissioning Toolkit, an update to the original toolkit published back in September 2013.

The updated toolkit sets out key commissioning responsibilities, with the intention of bringing clarity to an often highly fragmented commissioning landscape. The toolkit is also intended to aide commissioners in commissioning cost-effective services which are tailored to the needs of people with hepatitis C, by setting out how to ensure a clear, connected and properly funded hepatitis C care pathway, as well as providing good

practice examples.

As well as aiding commissioners, the toolkit will help service providers to understand who is commissioning what as we try to increase hepatitis C testing and treatment as well as introduce savings and efficiencies. As such, the toolkit will be an invaluable resource for everyone working in the field of hepatitis C. You can access the toolkit here.

# Last few HCV Action Manchester roadshow places available



Final preparations are underway for HCV Action and Public Health England's

hepatitis C good practice roadshow in Manchester, which is being held on Tuesday  $13^{\rm th}$  December.

The roadshow, which is the final of three such events to be held in England this year, features a line-up of speakers that includes Mike Burrows (Managing Director of the Greater Manchester Academic Health Science Network), Will Morton (Public Health Registrar at Public Health England), Dr Andrew Ustianowski (Consultant in Infectious Diseases at North Manchester General Hospital), Dr Kristina Poole (Specialist Registrar in Health Protection for Public Health England) and Dr Michael Gregory (Regional Clinical Director of Specialised Commissioning, NHS England).

<u>Policy</u>. The paper examines how interferon-free treatments for hepatitis C are being understood and experienced by patients and can be accessed <u>here</u>.

Share your good practice...

If you would like your service to be featured as a good practice case study on the HCV Action website, please send an email to hcvaction@hepctrust.org.uk.

We want to keep HCV Action's membership updated on news and events from across the country.

If you have any news you would like to share with colleagues or would like to publicise an event please email details to hcvaction@hepctrust.org.uk.

As well as the presentations, there will also be a panel discussion and afternoon workshops focusing on the work of the ODN in the region, awareness and testing in drug services, and hepatitis C in South Asian Communities.

There are still a few places available for the event, which forms part of a broader HCV Action 'action week' in the area, with quick registration being advised. You can view the full programme and venue details and register for the event here.

# Update on opt-out BBV testing in prisons published

The latest BBV Bulletin, a quarterly update report on the introduction of opt-out BBV testing in prisons published by Public Health England, NHS England and

BBV bulletin: Special Edition
Out totiny addition report of the antivolution or option 88V insting
prisons from 1981, 811 S registed and 100.15

Introduction: Phase 2 Pathfinder Prison Evaluation

Since the last buildin was published, work has been underway to fealise the
same 11, October 2016

Introduction: Phase 2 Pathfinder Prison Evaluation

Since the last buildin was published, work has been underway to fealise the
Pathfinder prison. To the end, too task and frishing prujue meetings were convened
toolselp granging on pase 2 conditionary design (edited) and evaluation of
summary of the key forcings from the phase 2 evaluation. A glossary is included
towards the end of the document Bedgraption firms also and but the 88V option
which are to the second of the prison and the second of the second of the prison exhibition on the board on the Public Heath England (Pitt) weeked at a phase 4
which prisons are allation for Egalthider program than the phase 2 evaluation can be found on the Public Heath England (Pitt) weeked at a phase 4
which prisons are allation for Egalthider program may be the support provided to
possibly algorized pathfinder program may be the support provided to
possibly algorized prisons for the phase 2 evaluation was primary on pathed
timage into care. To this end, consideration was given to the support provided to
possibly algorized prisons for the phase 2 evaluation was primary on pathed
timage into care. To this end, consideration was given to the support provided to
possibly algorized prisons to the phase 2 evaluation of the phase

NOMS, is now available to view on the HCV Action website.

The report provides an overview of results and findings from the 'phase 2 pathfinder' prisons, as well as a range of recommendations, including for prison healthcare teams to work more closely with local ODNs to improve uptake and completion of hepatitis C treatment, and for healthcare providers in prisons to improve their data collection methods on testing and treatment.

The report can be read in full here.

HCV Action is co-funded by AbbVie, BMS, Gilead, and MSD. The Hepatitis C Trust provides secretariat support to HCV Action

Visit www.hcvaction.org.uk and follow us on twitter @HCVAction



Please encourage colleagues to join HCV Action for free hepatitis C related updates and tools by emailing their full contact details to hcvaction@hepctrust.org.uk.